The developing trend of monoclonal antibodies in the treatment of colorectal cancer

Bibliography

• HARRIS M: Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. (2004) 5:292-302.
   PubMed Web of Science ®Google Scholar
• CARTER P: Improving the efficacy of antibody-based cancer therapies.Nat. Rev. Cancer (2001) 1:118-129.
   PubMed Web of Science ®Google Scholar
• ARTEAGA CL: The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J. Clin. Oncol. (2001) 19:32S-40S.
   PubMed Web of Science ®Google Scholar
• SALOMON DS, BRANDT R, CIARDIELLO F et al.: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. (1995) 19:183-232.
   PubMed Web of Science ®Google Scholar
• CARPENTER G: Receptors for epidermal growth factor and other polypeptide mitogens. Ann. Rev. Biochem. (1987) 56:881-914.
   PubMed Web of Science ®Google Scholar
• CARPENTER G, COHEN S: Epidermal growth factor. J. Biol. Chem. (1990) 265:7709-7712.
   PubMed Web of Science ®Google Scholar
• KIM ES, KHURI FR, HERBST RS: Epidermal growth factor receptor biology (IMC-C225). Curr. Opin. Oncol. (2001)13:506-513.
   PubMed Web of Science ®Google Scholar
• WELLS A: EGF receptor. Int. J.Biochem. Cell Biol. (1999) 31:637-643.
   PubMed Web of Science ®Google Scholar
• YASUI W, SUMIYOSHI H, HATA J et al.: Expression of epidermal growth factor receoptor in human gastric and colonic carcinomas. Cancer Res.(1988) 48:137-141.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN NI, PREWETT M, ZUKLYS K et al.: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumour xenograft model. Clin. Cancer Res. (1995) 1:1311-1318.
   PubMed Web of Science ®Google Scholar
• HUANG SM, BOCK JM, HARARI PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. (1999) 59:1935-1940.
   PubMed Web of Science ®Google Scholar
• WU X, FAN Z, MASUI H et al.: Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J. Clin. Invest. (1995) 95:1897-1907.
   PubMed Web of Science ®Google Scholar
• WU X, RUBIN M, FAN Z et al.: Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene (1996) 12:1397-1403.
   PubMed Web of Science ®Google Scholar
• LIU B, FANG M, SCHMIDT M et al.: Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br. J. Cancer (2000) 82:1991-1999.
   PubMed Web of Science ®Google Scholar
• HUANG SM, HARARI PM: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. (2000) 6:2166-2174.
   PubMed Web of Science ®Google Scholar
• NARAMURA M, GILLIES SD, MENDELSOHN J et al.: Therapeutic potential of chimeric and murine anti-epidermal growth factor receptor antibodies in a metastasis model for human melanoma. Cancer Immunol. Immunother. (1993) 37:343-349.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM D, HUMBLET Y, SIENA S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. (2004) 351:337-345.
   PubMed Web of Science ®Google Scholar
• SALTZ L, RUBIN M, HOCHSTER H et al.: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. (2001):Abstract 7.
   Google Scholar
• SALTZ LB, MEROPOL NJ, LOEHRER PJ Sr. et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. (2004) 22:1201-1028.
   PubMed Web of Science ®Google Scholar
• SALTZ LB, LENZ H, HOCHSTER H et al.: Randomized Phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 3508.
   Google Scholar
• DIAZ RUBIO E, TABERNERO J, VAN CUTSEM E et al.: Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international Phase II study. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 3535.
   Google Scholar
• ROUGIER P, RAOUL J-L, VAN LAETHEM J-L et al.: Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA. Proc. Am. Soc. Clin. Oncol. (2004):Abstract 3513.
   PubMedGoogle Scholar
• VENOOK A, NIEDZWIECKI D, HOLLIS D et al.: Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX)±cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. Proc. Am. Soc. Clin. Oncol. (2006) 24:Abstract 3509.
   Google Scholar
• ABUBAKR Y, ENG C, PAUTRET V et al.: Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): safety analysis of 800 patients in a randomized Phase III trial (EPIC). Proc. Am. Soc. Clin. Oncol. (2006) 24:Abstract 3556.
   Google Scholar
• BADARINATH S, MITCHELL EP, JENNIS A et al.: Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): preliminary safety analysis of a randomized Phase III trial. Proc. Am. Soc. Clin. Oncol. (2004):Abstract 3531.
   Google Scholar
• JENNIS A, POLIKOFF J, MITCHELL E et al.: Erbitux (Cetuximab) plus FOLFOX for colorectal cancer (EXPLORE): preliminary efficacy analysis of a randomized Phase III trial. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 3574.
   Google Scholar
• ARTEAGA CL: Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist (2002) 4(Suppl. 7):31-39.
   Google Scholar
• NICHOLSON RI, GEE JM, HARPER ME: EGFR and cancer prognosis. Eur. J. Cancer (2001) 4(Suppl. 37):S9-S15.
   Web of Science ®Google Scholar
• LENZ HJ, MAYER RJ, GOLD PJet al.: Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc. Am. Soc. Clin. Oncol. (2004):Abstract 3510.
   Google Scholar
• CHUNG KY, SHIA J, KEMENY NE et al.: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. (2005) 23:1803-1810.
   PubMed Web of Science ®Google Scholar
• MALIK I, HECHT JR, PATNAIK A et al.: Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). Proc. Am. Soc. Clin. Oncol. (2005):Abstract 3520.
   Google Scholar
• MEROPOL NJ, BERLIN J, HECHT JR et al.: Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2003):Abstract 1026.
   Google Scholar
• PEETERS M, VAN CUTSEM E, SIENA S et al.: A Phase III, multicenter, randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) versus BSC alone in patients with metastatic colorectal cancer (mCRC), 97th AACR Annual Meeting, 2006.
   Google Scholar
• BERLIN J, MALIK I, PICUS J et al.: Panitumumab therapy with irinotecan, 5-fluorouracil, and leucovorin (IFL) in patients with metastatic colorectal cancer. Ann. Oncol. (2004) 15 (Suppl. 3):iii70:Abstract 265PD.
   Google Scholar
• BERLIN J, POSEY J, TCHEKMEDYIAN S et al.: First line therapy of panitumumab, a fully human antibody, in combination with FOLFIRI for the treatment of metastatic colorectal cancer. Eur. J. Cancer Suppl. (2005) 3:185:Abstract 653.
   Google Scholar
• TRARBACH T, BEYER T, SCHLEUCHER N et al.: Randomized Phase I pharmacodynamic study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in patients with advanced EGFR-expressing tumors: preliminary results of an ongoing study. Clin. Cancer Res. (2003) 9:6069S:Abstract A112.
   PubMedGoogle Scholar
• TABERNERO J, ROJO F, JIMENEZ E et al.: A Phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-(q2w) or every 3-week (q3w) 1-hour (h) infusion EMD72000, an humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with advanced tumors. Proc. Am. Soc. Clin. Oncol. (2003) 22:192:Abstract 770.
   Google Scholar
• VANHOEFER U, TEWES M, ROJO F et al.: Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J. Clin. Oncol. (2004) 22:175-184.
   PubMed Web of Science ®Google Scholar
• VAN CUTSEM E, HUMBLET Y, GELDERBLOM H et al.: Cetuximab dose-escalation study in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic and efficacy data of a randomized study. Proceedings of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, Fla. 2007:Abstract 237.
   Google Scholar
• FERRARA N, GERBER HP: The role of vascular endothelial growth factor in angiogenesis. Acta Haematol. (2001) 106:148-156.
   PubMed Web of Science ®Google Scholar
• FERRARA N: Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. (2002) 29:10-14.
   PubMed Web of Science ®Google Scholar
• FERRARA N, GERBER HP, LECOUTER J: The biology of VEGF and its receptors. Nat. Med. (2003) 9:669-676.
   PubMed Web of Science ®Google Scholar
• KIM KJ, LI B, HOUCK K et al.: The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors (1992) 7:53-64.
   PubMedGoogle Scholar
• PRESTA LG, CHEN H, O'CONNOR SJ et al.: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. (1997) 57:4593-4599.
   PubMed Web of Science ®Google Scholar
• KABBINAVAR F, HURWITZ H, FEHRENBACHER L et al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. (2003) 21:60-65.
   PubMed Web of Science ®Google Scholar
• HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl.J. Med. (2004) 350:2335-2342.
   PubMed Web of Science ®Google Scholar
• KABBINAVIR FF, SCHULZ J, McCLEOD M et al.: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized Phase II trial. J. Clin. Oncol. (2005) 23:3697-3705.
   PubMed Web of Science ®Google Scholar
• SALTZ LB, CLARKE S, DIAZ-RUBIO E et al.: Bevacizumab (Bev) in combination with XELOX or FOLFOX 4: efficacy results from XELOX-1/NO16966, a randomized Phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). Results from the 2007 Gastrointestinal Cancers Symposium.
   Google Scholar
• GIANTONIO BJ, CATALANO PJ, MEROPOL NJ et al.: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. ASCO (2005):Abstract 2.
   Google Scholar
• HOCHSTER HS, Welles L, Hart L, et al.: Bevacizumab (B) with oxaliplatin (O)-based chemotherapy in the first-line therapy of metastatic colorectal cancer (mCRC): preliminary results of the randomized ‘TREE-2’ trial. GI ASCO (2005):Abstract 241.
   Google Scholar
• HEDRICK E, KOZLOFF M, HAINSWORTH J et al.: Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE). Proceedings of the American Society of Clinical Oncology. (2006):Abstract 3536.
   Google Scholar
• VAN CUTSEM E, MICHAEL M, BERRY S et al.: Preliminary safety of bevacizumab with first-line FOLFOX, CAPOX, FOLFIRI and capecitabine for mCRC: first BEA Trial. GI ASCO (2006):Abstract 250.
   Google Scholar
• HURWITZ HI, FEHRENBACHER L, HAINSWORTH JD et al.: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J. Clin. Oncol. (2005) 23:3502-3508.
   PubMed Web of Science ®Google Scholar
• BETSHOLTZ C, ARMULIK A: Homeostatic functions of vascular endothelial growth factor in adult microvasculature. Am. J. Physiol. Heart Circ. Physiol. (2006) 290: H509-H511.
   PubMed Web of Science ®Google Scholar
• WULFF C, WILSON H, WIEGAND SJ et al.: Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. Endocrinology (2002) 143:2797-2807.
   PubMed Web of Science ®Google Scholar
• KONNER J, DUPONT J: Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity. Clin. Colorectal Cancer (2004) 4(Suppl. 2):S81-S85.
   PubMedGoogle Scholar
• LAU SC, ROSA DD, JAYSON G: Technology evaluation: VEGF Trap (cancer), Regeneron/Sanofi-Aventis. Curr. Opin. Mol. Ther. (2005) 7:493-501.
   PubMed Web of Science ®Google Scholar
• WONG AK, ALFERT M, CASTRILLON DH et al.: Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome. Proc. Natl. Acad. Sci. USA (2001) 98:7481-7486.
   PubMed Web of Science ®Google Scholar
• DUPONT J, SCHWARTZ L, KOUTCHER J et al.: Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously to patients with advanced solid malignancies. Proc. Am. Soc. Clin. Oncol. (2004):Abstract 3009.
   Google Scholar
• DUPONT J, CAMASTRA D, GORDON MS et al.: Phase I study of VEGF Trap in patients with solid tumors and lymphoma. Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 776.
   Google Scholar
• RIXE O, VERSLYPE C, MERIC JB et al.: Safety and pharmacokinetics of intravenous VEGF Trap plus irinotecan, 5-fluorouracil, and leucovorin in a combination Phase I clinical trial of patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2006) 24:Abstract 13161.
   Google Scholar
• POSEY JA, NG TC, YANG B et al.: A Phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma.Clin. Cancer Res. (2003) 9:1323-1332.
   PubMed Web of Science ®Google Scholar
• TRARBACH T, THOMAS AL, BARTEL C et al.: Preliminary Phase I results of the oral, once-daily angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) in combination with chemotherapy for the treatment of metastatic colorectal cancer. Eur. J. Cancer (2003) 1(Suppl. 5):S 91:Abstract 297.
   Google Scholar
• STEWARD WP, THOMAS A, MORGAN B et al.: Expanded Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2004) 23:259:Abstract 3556.
   Google Scholar
• HECHT JR, TRARBACH E, JAEGER E et al.: A randomized, double-blind, placebo controlled, Phase III study in patients (Pts) with metastatic adenocarcinoma of the colonor rectum receiving first-line chemotherapy with oxaliplatin/5-fluoruoracil/leucovorin and PTK787/Zk222584 or placebo (CONFIRM-1). J. Clin. Oncol. (2005) 23(16s):1090s:Abstract LBA3.
   Google Scholar
• Planned interim analysis of CONFIRM 2 trial of PTK/ZK indicates low probability of demonstrating overall survival benefit in second-line therapy for metastatic colorectal cancer [Press Release]. Novartis, July 28, 2005.
   Google Scholar
• GOODWIN RA, TUTTLE SE, BUCCI DM: Tumor-associated antigen expression of primary and metastatic colorectal carcinomas detected by monoclonal antibody 17-1A. Am. J. Clin. Pathol. (1987) 88:462-477.
   PubMed Web of Science ®Google Scholar
• BALZAR M, WINTER J, DE BOER CJ, LITVINOV NV: The biology of the 17-1A antigen (Ep-CAM). J. Mol. Med. (1999) 17:699-712.
   Web of Science ®Google Scholar
• GOLDBERG RM: Lessons learned from the edrecolomab story: how a checkered past became a checkered flag for monoclonal antibodies in colorectal cancer therapy. Onkologie (2005) 28:311-312.
   PubMed Web of Science ®Google Scholar